U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06959511) titled 'Neoadjuvant Treatment With Zanzalintinib for Advanced Thyroid Cancer' on April 28.

Brief Summary: To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.

Study Start Date: Oct. 22, 2025

Study Type: INTERVENTIONAL

Condition: Neoadjuvant Treatment Thyroid Cancer

Intervention: DRUG: Zanzalintinib

Given by po

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M.D. Anderson Cancer Center

Disclaimer: Curated by HT Syndication....